vTv Therapeutics
VTVT
19 hedge funds and large institutions have $357K invested in vTv Therapeutics in 2018 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 3 increasing their positions, 8 reducing their positions, and 11 closing their positions.
0.12% less ownership
Funds ownership: 0.2% → 0.09% (-0.12%)
30% less funds holding
Funds holding: 27 → 19 (-8)
63% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 8
71% less capital invested
Capital invested by funds: $1.22M → $357K (-$860K)
73% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 11
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
+$53.9K |
| 2 |
TSS
Two Sigma Securities
New York
|
+$19.9K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$10.5K |
| 4 |
BlackRock
New York
|
+$985 |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$235 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$162K |
| 2 |
CWG
C WorldWide Group
Copenhagen,
Denmark
|
-$74K |
| 3 |
PP
Paloma Partners
Greenwich,
Connecticut
|
-$53K |
| 4 |
ARTA
A.R.T. Advisors
New York
|
-$52.4K |
| 5 |
Jane Street
New York
|
-$38K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Manulife (Manufacturers Life Insurance)
Canada,
Ontario, Canada
| – | -$2K | -30 | Closed |
|
|
TRCT
27
Tower Research Capital (TRC)
New York
| – | -$1K | -21 | Closed |
|
|
MAM
28
Meeder Asset Management
Dublin,
Ohio
| – | -$944 | -15 | Closed |
|
|
SWP
29
Stratos Wealth Partners
Beachwood,
Ohio
| – | +$47 | +1 | New |
|
VTVT Hedge Fund Activity: Q3 2018 in Review
19 of the 4,375 institutional investors tracked by Wall St. Rank reported a position in vTv Therapeutics (VTVT) for Q3 2018, worth a combined $357K — down 71% from $1.22M a quarter earlier.
Sellers outnumbered buyers: 11 funds closed out of VTVT and 3 opened new positions — a net loss of 8 holders — while 8 trimmed existing stakes and 3 added.
The largest buyer was Panagora Asset Management, opening a new position worth an estimated $53.9K. The largest seller was Deutsche Bank, exiting entirely with an estimated $162K sold.
- 19 institutional investors held vTv Therapeutics (VTVT) as of Q3 2018, down from 27 in Q2 2018.
- Funds reported $357K of vTv Therapeutics stock for Q3 2018, down 71% quarter-over-quarter.
- 3 funds opened new vTv Therapeutics positions in Q3 2018 and 11 closed out, a net change of -8 holders.
- The largest vTv Therapeutics buyer in Q3 2018 was Panagora Asset Management, an estimated $53.9K added.
- The largest vTv Therapeutics seller in Q3 2018 was Deutsche Bank, an estimated $162K sold.
Based on aggregated 13F filings for Q3 2018.